Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2021-09-13 , DOI: 10.1111/dom.14549
Jochen Seufert ₁ , Peter Wiesli ₂ , Andreas Fritsche _{3,

4} , Helmut Anderten ₅ , Katrin Pegelow ₆ , Stefan Pscherer ₇ , Martin Pfohl ₈

Affiliation

This study evaluated the effectiveness and safety of switching the basal insulin (BI) in a BI-supported oral therapy (BOT) to insulin glargine 300 U/ml (Gla-300) in adults with inadequately controlled type 2 diabetes (T2D).

中文翻译：

在口服基础胰岛素支持的 2 型糖尿病患者中将基础胰岛素转换为 300 U/ml 甘精胰岛素：有效性和安全性的观察性试验

本研究评估了在控制不佳的 2 型糖尿病 (T2D) 成人患者中，将基础胰岛素 (BI) 中的基础胰岛素 (BI) 转换为 300 U/ml 甘精胰岛素 (Gla-300) 的有效性和安全性。

更新日期：2021-09-13

点击分享查看原文

点击收藏

阅读更多本刊最新论文